Home » FDA Panel Recommends Against Approval of Nonprescription Mevacor
FDA Panel Recommends Against Approval of Nonprescription Mevacor
Merck announced that the U.S. Food and Drug Administration’s (FDA) joint panel of the Nonprescription Drugs Advisory Committee (NDAC) and the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted against recommending approval at this time of the over-the-counter (OTC) use of Mevacor (lovastatin) 20 mg to help lower LDL cholesterol, which may prevent a first heart attack.
Business Wire
Business Wire
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May